Abstract
Monocytes and platelets play key roles in atherosclerosis and thrombosis, and circulating monocyte-platelet aggregates (MPA) in blood have been widely proposed as surrogate biomarkers for cardiovascular risk stratification and monitoring anti-platelet therapies. However, conventional MPA characterization is based on whole blood fixation and flow cytometry analysis which adversely affect cell viability and detection accuracy due to significant leukocyte and platelet contamination. Herein, we introduce a rapid and label-free microfluidic approach for complete size-based fractionation of peripheral blood mononuclear cells (PBMCs) into monocytes, lymphocytes and platelets. The developed biochip enables gentle sorting of intact MPA in the enriched monocytes with efficient depletion of lymphocytes and platelets for accurate MPA quantification. We first compared the developed microfluidic technology (Dean Flow Fractionation, DFF) with standard magnetic negative isolation (MACS), and observed that DFF-sorted monocytes had similar viability, purity and key immune functions (phagocytosis, macrophage differentiation) as MACS-sorted monocytes. As proof-of-concept for diabetes testing, we isolated and characterized monocytes/MPA from a cohort of healthy (n=5) and type 2 diabetes mellitus (T2DM) subjects (n=8) in PBMCs and DFF-sorted monocytes. High speed imaging, immunofluorescence and flow cytometry analysis clearly indicated higher levels of MPA in T2DM patients (P-1) label-free isolation of monocyte/MPA from PBMCs, and can be further developed into a clinical tool for point-of-care cardiovascular risk stratification in metabolic disorders including T2DM.
Funding Information
  • Agency for Science, Technology and Research
  • Ministry of Education - Singapore (RG53/18)
  • National Research Foundation Singapore (NMRC/BNIG/2038/2015)
  • Nanyang Technological University

This publication has 36 references indexed in Scilit: